PatSnap/clinical-trial huggingface dataset:
Clinical trial NCT03602053: Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia
Official title: An Open-label, Randomized, Controlled, Single Centre, Phase IIb Study to Assess the Immunogenicity, Reactogenicity and Safety of Three Live Oral Rotavirus Vaccines, ROTAVAC® , ROTAVAC 5CM and Rotarix® in Healthy Zambian Infants
Conditions: Diarrhea
Diarrhea Rotavirus
Summary: The study is being conducted to evaluate and compare the immunogenicity of ROTAVAC® and ROTAVAC 5D 28 days after the last dose of the vaccine, when administered to infants in a three-dose schedule at 6, 10 and 14 weeks of age.
The study will also assess the reactogenicity of the vaccine 7 days after each vaccination and safety from first vaccination up to 4 weeks after the last vaccination with ROTAVAC® and ROTAVAC 5D, and of Rotarix® when administered to infants in a two-dose schedule at 6 and 10 weeks of age.
Interventions:
description: 0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
name: ROTAVAC®
type: Biological
description: 0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
name: ROTAVAC 5D
type: Biological
description: 1.5 ml of the liquid vaccine will be administered orally twice at 6 and 10 weeks of age.
name: Rotarix®
type: Biological
Study arms:
design_group_description: Bharat Biotech International Ltd's new Rotavirus vaccine, ROTAVAC 5D is a live, attenuated G9P[11] monovalent vaccine at a dose of 0.5mL containing NLT log 10^5.0 focus forming units (FFU) per dose. 5D is in liquid form.
design_group_title: ROTAVAC 5D
design_group_type: Experimental
design_group_description: Bharat Biotech International Ltd's licensed rotavirus vaccine, ROTAVAC® is a live, attenuated G9P[11] monovalent vaccine at a dose of 0.5mL containing NLT log 10^5.0 focus forming units (FFU) per dose. ROTAVAC® is in frozen form and is thawed till fully liquid prior to administration.
design_group_title: ROTAVAC®
design_group_type: Experimental
design_group_description: GSK Biologicals' licensed rotavirus vaccine, Rotarix® is a live attenuated RIX4414 strain of human rotavirus of the G1P[8] type containing not less than 106.0 CCID50 (cell culture infectious dose 50%) of the RIX 4414 strain of human rotavirus.
design_group_title: Rotarix®
design_group_type: Active Comparator
Sponsor: Centre For Infectious Disease Research
Collaborators: Christian Medical College & Hospital
Bharat Biotech International Ltd.
Program for Appropriate Technology in Health
Children's Hospital & Medical Center
Drug name mappings:
name: 轮状病毒疫苗116E(Bharat Biotech International Ltd.)
lang: CN
name: Rotavirus vaccine 116E(Bharat Biotech International Ltd.)
lang: EN
Clinical trial NCT03926754: Beta 3 Agonist Treatment in Heart Failure-2
Official title: Beta 3 Agonist Treatment in Heart Failure-2
Conditions: Heart Failure With Reduced Ejection Fraction NYHA Class III-IV
Summary: Objective: The objective of the study is to assess the structural and functional cardiac effects of treatment with the beta 3 AR agonist Mirabegron in patients with moderate to severe chronic heart failure (LVEF<35%, NYHA III-IV).
The study is a randomized, placebo-controlled, double-blinded trial in two phases with two hypotheses:
Chronic study - study A: Long-term treatment (3 months) with the β3 adrenergic receptor agonist Mirabegron is beneficial in patients with moderate to severe human heart failure
Invasive study - Study B: Administration of Mirabegron in patients with heart failure leads to an immediate increase in cardiac output at a constant or reduced left ventricular filling pressure during submaximal exercise
Specific aims
1. Determine safety of administration of Mirabegron to patients with moderate to severe heart failure.
2. Determine if treatment with Mirabegron for 3 months induces beneficial cardiac structural remodelling in patients with moderate to severe heart failure. In an open-label follow-up to determine the effects of Mirabegron after an extended duration (a total of 12 months).
3. Determine if Mirabegron improves symptoms and exercise capacity as indicated by questionnaires and 6 min walk test in patients with moderate to severe heart failure.
4. Determine effects of Mirabegron on cardiac conduction, repolarisation and rhythms and arrhythmias in patients with moderate to severe heart failure.
5. Determine effects of Mirabegron on circulating biomarkers in patients with moderate to severe heart failure.
6. Determine the immediate and short term haemodynamic effects of Mirabron as measured by CT and invasively.
Interventions:
description: Study A The maximum tolerated dose up to a maximum of 300 mg per day for 26 weeks.<br/>Study B One single dose of 300 mg at day one followed by 150 mg x 2 for 1 week (8-11 days).
name: Mirabegron
other_name: Placebo
type: Drug
Study arms:
design_group_description: Active treatment arm (mirabegron)
design_group_title: Mirabegron
design_group_type: Active Comparator
design_group_description: Placebo
design_group_title: Placebo
design_group_type: Placebo Comparator
Sponsor: Rigshospitalet
Collaborators: Royal North Shore Hospital
Hillerød Hospital
Herlev Hospital
Hvidovre University Hospital
Bornholms Hospital
Drug name mappings:
name: 米拉贝隆
lang: CN
name: Mirabegron
lang: EN
name: ミラベグロン
lang: JP
Clinical trial NCT01950299: Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)
Official title: Interleukin-1 Blockade With Anakinra in Patients With ST-segment Elevation Myocardial Infarction - the Virginia Commonwealth University Anakinra Remodeling Trial 3
Conditions: Acute Myocardial Infarction
Summary: VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI) measuring the effects on the acute rise and fall of the plasma C reactive protein levels during the first 14 days.
Interventions:
description: Anakinra 100 mg starting immediately and then every 24 hours
name: Anakinra 100 mg
other_name: Kineret
type: Drug
description: Anakinra 100 mg starting 12 hours after first dose and then every 24 hours (so that Anakinra is given every 12 hours)
name: Anakinra 100 mg
other_name: Kineret
type: Drug
description: Placebo 0.67 ml injections twice daily
name: Placebo
other_name: Placebo injections twice daily
type: Drug
Study arms:
design_group_description: Anakinra 100 mg daily for 14 days
design_group_title: Anakinra (standard dose)
design_group_type: Experimental
design_group_description: Anakinra 100 mg twice daily for 14 days
design_group_title: Anakinra (high dose)
design_group_type: Experimental
design_group_description: Placebo for 14 days
design_group_title: Placebo
design_group_type: Placebo Comparator
Sponsor: Virginia Commonwealth University
Collaborators: National Heart, Lung & Blood Institute
National Institutes of Health
Drug name mappings:
name: 安纳白介素
lang: CN
name: Anakinra (Amgen)
lang: EN
Clinical trial NCT03107377: Phase 2B/3 Double-blinded Placebo-controlled
Official title: Phase 2B Double-blind Placebo-controlled Efficacy Trial of EVO100 (Previously Known as Amphora ® Gel) for the Prevention of Acquisition of Urogenital Chlamydia Trachomatis Infection
Conditions: Chlamydia Trachomatis Infection
Summary: Phase 2B double-blind placebo-controlled efficacy trial of EVO100 (previously known as Amphora ® Gel) for the prevention of acquisition of urogenital Chlamydia trachomatis infection
Interventions:
description: 5 g dose applied up to 1 hour prior to coitus
name: EVO100
type: Drug
description: 5 g dose applied up to 1 hour prior to coitus
name: Placebo
type: Drug
Study arms:
design_group_description: A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.
design_group_title: EVO100
design_group_type: Active Comparator
design_group_description: An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.
design_group_title: Placebo
design_group_type: Placebo Comparator
Sponsor: Evofem, Inc.
Collaborators: ICON Government & Public Health Solutions, Inc.
Drug name mappings:
name: L-乳酸/柠檬酸/酒石酸氢钾
lang: CN
name: Citric Acid/Lactic Acid/Potassium Bitartrate
lang: EN
Clinical trial NCT00869986: A Study for Patients With Relapsing Remitting Multiple Sclerosis
Official title: A Double Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis
Conditions: Relapsing Remitting Multiple Sclerosis
Summary: The purpose of this study is to test if dirucotide is safe and effective in treating patients with relapsing remitting multiple sclerosis.
Interventions:
description: 500mg, intravenous, every 6 months for 15 months
name: dirucotide
other_name: LY2820671
MBP8298
type: Drug
description: intravenous, once every six months for 15 months
name: placebo
type: Drug
Study arms:
design_group_title: Dirucotide
design_group_type: Experimental
design_group_title: Placebo
design_group_type: Placebo Comparator
Sponsor: Eli Lilly & Co.
Collaborators: BioMS Technology Corp.
Drug name mappings:
name: Dirucotide
lang: EN
Clinical trial NCT00027976: Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses
Official title: A Phase II/III Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of Celecoxib In Subjects With Actinic Keratoses
Conditions: Precancerous Condition
Summary: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be an effective way to prevent actinic keratoses.
PURPOSE: Randomized phase II/III trial to determine the effectiveness of celecoxib in preventing skin cancer in patients who have actinic keratoses.
Interventions:
name: celecoxib
type: Drug
name: Placebo
type: Drug
Study arms:
design_group_description: receipt of active drug
design_group_title: Group 1 active arm
design_group_type: Experimental
design_group_description: receipt of active drug
design_group_title: Group 2 active arm
design_group_type: Experimental
design_group_description: receipt of placebo
design_group_title: group 2 placebo arm
design_group_type: Experimental
Sponsor: The University of Alabama at Birmingham
Collaborators: National Cancer Institute
Drug name mappings:
name: 塞来昔布
lang: CN
name: Celecoxib
lang: EN
name: セレコキシブ
lang: JP
Clinical trial NCT00845364: Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery
Official title: Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery
Conditions: Myocardial Reperfusion Injury
Cardiac Output, Low
Summary: Open-heart surgery causes injury of the heart muscle. Although this is usually mild, temporary and reversible, if it is severe it can endanger life and require additional high cost care. During surgery, techniques are used to protect the heart from injury, but these remain imperfect. This study assesses the effect of facilitating sugar metabolism (a more efficient fuel) by the heart muscle using the drug Perhexiline given before the operation. This treatment has a sound experimental basis for improving outcome. If this improvement is confirmed surgical results could be improved. The investigators will be studying heart function, heart muscle energy stores and chemicals which quantify the amount of heart muscle injury. The investigators' hypothesis is that Perhexiline will improve the protection of the heart by decreasing damage that may occur during heart surgery.
Interventions:
description: Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
name: Perhexiline
other_name: PEXSIG
type: Drug
description: Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
name: Placebo marked PEXSIG
type: Drug
Study arms:
design_group_description: Pre-operative administration of Perhexiline tablets according to dosing schedule
design_group_title: Perhexiline
design_group_type: Experimental
design_group_description: Pre-operative administration of placebo tablets according to dosing schedule
design_group_title: Placebo
design_group_type: Placebo Comparator
Sponsor: University Hospitals Birmingham Charity
Collaborators: Brighton and Sussex University Hospitals NHS Trust
British Heart Foundation
University of Birmingham
Drug name mappings:
name: 马来酸哌克昔林
lang: CN
name: Perhexiline Maleate
lang: EN
Clinical trial NCT04139213: Medication Maintenance Therapy in Community Pharmacy Settings
Official title: Comparing Medication Maintenance in Comprehensive Community and Pharmacy Settings to Enhance Engagement
Conditions: Opioid-use Disorder
Summary: The goal of this study is to compare pharmacy-based medication assisted treatment (MAT) with usual care MAT for people with opioid use disorder.
Interventions:
description: To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly or monthly basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.
name: buprenorphine/naloxone oral product
other_name: Suboxone
type: Drug
description: To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
name: injectable naltrexone
other_name: Vivitrol
type: Drug
description: Patients randomized to the pharmacy study arm and on a stable dose of buprenorphine/naloxone or naltrexone will receive maintenance care at the pharmacy for up to three months. Patients will visit for check-ins with a pharmacist on a monthly, weekly, or more frequent basis, depending on the individual treatment plan. Patients on buprenorphine/naloxone will be dispensed their medication at study visits, whereas patients taking injectable naltrexone will be dispensed it monthly by the pharmacist. All patients will visit the pharmacy at least monthly for addiction care (assessment, toxicological testing).
name: Pharmacy maintenance addiction care
type: Other
description: To augment care for patients receiving injectable naltrexone for the treatment of OUD and treat cravings that may arise before their scheduled injection, patients prescribed injectable naltrexone may be provided a several day supply of oral naltrexone by a study pharmacist under a collaborative pharmacy practice agreement. The expected dose of oral naltrexone will be approximately 25-50 mg daily.
name: oral naltrexone
type: Drug
Study arms:
design_group_description: usual medication assisted treatment for maintenance care of opioid use disorder
design_group_title: Usual care
design_group_type: Active Comparator
design_group_description: pharmacy-based medication assisted treatment for maintenance care of opioid use disorder
design_group_title: Pharmacy MAT
design_group_type: Experimental
Sponsor: Brown University Health
Collaborators: The Miriam Hospital
University of Rhode Island
Drug name mappings:
name: 盐酸纳曲酮
lang: CN
name: Naltrexone Hydrochloride
lang: EN
name: 丁丙诺啡纳洛酮
lang: CN
name: Buprenorphine Hydrochloride/Naloxone Hydrochloride
lang: EN
Clinical trial NCT04817215: Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
Official title: A Double-Blinded, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Uncontrolled Type 2 DM Subjects on Diet Control Alone, Metformin Monotherapy, or Two or Three Oral Glucose-lowering Agents
Conditions: Diabetes Mellitus, Type 2
Summary: To compare the efficacy of ORMD-0801 to placebo in improving glycemic control as assessed by A1C in inadequately controlled T2DM subjects on diet control alone or on diet control and metformin monotherapy or two or three oral glucose-lowering agents.
To assess the safety of repeat administration of ORMD-0801 in inadequately controlled T2DM subjects on on diet control alone or on diet control and metformin monotherapy or two or three oral glucose-lowering agents.
Interventions:
description: Randomized to receive ORMD-0801 8 mg QD or 8 mg BID or matching placebo
name: ORMD-0801
type: Drug
Study arms:
design_group_title: Patients who are Drug naïve or diet controlled
design_group_type: Experimental
design_group_title: Patients on Metformin only
design_group_type: Experimental
design_group_title: Patients on two or three oral glucose-lowering agents
design_group_type: Experimental
Sponsor: King Hamad General Hospital
Collaborators: Royal College of Surgeons in Ireland - Medical University of Bahrain
Oramed Ltd.
Drug name mappings:
name: 重组人胰岛素（Oramed）
lang: CN
name: Insulin (Oramed)
lang: EN
Clinical trial NCT00080314: Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode
Conditions: Bipolar Disorder
Summary: The purpose of this study is to evaluate flexible doses (5-30mg) of aripiprazole versus placebo in patients with bipolar depression.
Interventions:
description: Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
name: Aripiprazole
other_name: Abilify
type: Drug
description: Tablets, Oral, 0 mg, Once daily, 8 weeks.
name: Placebo
type: Drug
Study arms:
design_group_title: A1
design_group_type: Active Comparator
design_group_title: A2
design_group_type: Placebo Comparator
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators: Otsuka America Pharmaceutical, Inc.
Drug name mappings:
name: 阿立哌唑
lang: CN
name: Aripiprazole
lang: EN
name: アリピプラゾール水和物
lang: JP
Clinical trial NCT00190645: To Evaluate the Safety of Duloxetine in Patients With Stress Urinary Incontinence
Official title: Long-Term Monitoring of Safety in Subjects Treated With Duloxetine for Stress Urinary Incontinence
Conditions: Stress Urinary Incontinence
Summary: The patients are being followed in this study to determine the safety of taking the medication Duloxetine for a long period of time. The patients participating in this study suffer from Stress Urinary Incontinence.
Interventions:
name: Duloxetine
type: Drug
Study arms:
Sponsor: Eli Lilly & Co.
Collaborators: Boehringer Ingelheim GmbH
Drug name mappings:
name: 盐酸度洛西汀
lang: CN
name: Duloxetine Hydrochloride
lang: EN
name: デュロキセチン塩酸塩
lang: JP
Clinical trial NCT04022967: ANRS 12372 MODERATO Study
Official title: Randomized, Non-inferiority Trial Comparing a Dual Maintenance Therapy Strategy With Dolutegravir + Lamivudine (DTG/3TC) or Atazanavir/Ritonavir + Lamivudine (ATV/r+3TC) Versus the Standard WHO First Line Triple Therapy Tenofovir + Lamivudine + Efavirenz (TDF+3TC+EFV) or Dolutegravir + Lamivudine + Tenofovir (DTG+3TC+TDF) in West and Central African HIV-1 Infected Patients
Conditions: HIV-1-infection
Summary: MODERATO is a phase III, open-label, randomized, multicenter, non-inferiority trial conducted in West and Central Africa (Cameroon, Côte d'Ivoire, Burkina Faso).
HIV-1 infected adults receiving first line ART with TDF+XTC+EFV or DTG+XTC+TDF virologically suppressed will be recruited and followed during 100 weeks.
The objective is to assess the non-inferiority of a strategy consisting of switching to a dual maintenance therapy (DTG+3TC or ATV/r+3TC), comparing to WHO standard first line regimen (TDF+3TC+EFV or DTG+3TC+TDF), in terms of virological success at 96 weeks
Interventions:
description: One daily tablet (50mg) during 96 weeks
name: dolutegravir
type: Drug
description: One daily tablet with atazanavir (300 mg) boosted with ritonavir (100 mg) during 96 weeks
name: atazanavir boosted with ritonavir
type: Drug
description: One daily tablet with tenofovir 245 mg + lamivudine (300 mg) + efavirenz (400 mg) during 96 weeks OR One daily tablet with dolutegravir 50 mg + lamivudine (300 mg) + tenofovir (300 mg) during 96 weeks
name: tenofovir + lamivudine +efavirenz or dolutegravir + lamivudine + tenofovir
type: Drug
description: One daily tablet (300mg) during 96 weeks
name: Lamivudine
type: Drug
Study arms:
design_group_title: Arm 1 : Dual maintenance therapy DTG+3TC
design_group_type: Experimental
design_group_title: Arm 2 : Dual maintenance therapy ATV/r+3TC
design_group_type: Experimental
design_group_title: Arm 3 : Reference triple therapy TDF+3TC+EFV or DTG+3TC+TDF
design_group_type: Active Comparator
Sponsor: France Recherche Nord & Sud SIDA HIV-Hepatites
Collaborators: Mylan Laboratories Ltd.
Drug name mappings:
name: 多替拉韦钠
lang: CN
name: Dolutegravir Sodium
lang: EN
name: ドルテグラビルナトリウム
lang: JP
name: 硫酸阿扎那韦/利托那韦
lang: CN
name: Atazanavir Sulfate/Ritonavir
lang: EN
name: 拉米夫定
lang: CN
name: Lamivudine
lang: EN
name: ラミブジン
lang: JP
Clinical trial NCT01324128: A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
Official title: An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared With Sevelamer Carbonate Followed by a Randomised Comparison of PA21 Maintenance Dose Versus PA21-Low Dose in Dialysis Patients With Hyperphosphataemia
Conditions: Chronic Kidney Disease Requiring Chronic Dialysis
Summary: This is a Phase 3, randomised, active controlled, multicentre study to investigate the safety and efficacy of PA21, a phosphate binder, for control of hyperphosphataemia in dialysis patients. The primary objective is to establish the efficacy of PA21 for lowering phosphate levels in these patients.
Interventions:
description: Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
name: PA21 (2.5 g tablet containing 500 mg iron)
type: Drug
description: Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day)
name: Sevelamer carbonate
type: Drug
description: Low dose comparator (1.25 g/day)
name: PA21-1 (1.25 g tablet containing 250 mg iron)
type: Drug
Study arms:
design_group_title: PA21 (2.5 g tablet)
design_group_type: Experimental
design_group_title: Sevelamer carbonate
design_group_type: Active Comparator
design_group_title: PA21-1 (1.25 g tablet)
design_group_type: Other
Sponsor: Corden Pharma Fribourg SA
Collaborators: Fresenius Medical Care North America Holdings LP
Drug name mappings:
name: 蔗糖铁
lang: CN
name: Iron sucrose
lang: EN
name: スクロオキシ水酸化鉄
lang: JP
Clinical trial NCT00259974: RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy
Official title: Double-blind Randomized Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy
Conditions: Polyneuropathy
Summary: Polyneuropathy associated with anti-MAG monoclonal IgM gammopathy is responsive of mainly a sensory deficit in predominantly males ,aged 40-70 years. Significantly high serum anti-MAG antibodies are linked with demyelinating features of the peripheral nerves.Rituximab, an anti-CD 20 monoclonal antibody is a new drug which reduces B-lymphocytes. This study will test the safety and efficacy of rituximab in the treatment of patients with anti-MAG polyneuropathy.
Interventions:
description: Rituximab
name: Rituximab
type: Drug
Study arms:
design_group_description: Rituximab
design_group_title: 1
design_group_type: Experimental
Sponsor: Assistance Publique des Hôpitaux de Paris SA
Collaborators: Centre Hospitalier Universitaire Pitie-Salpetriere
Hospices Civils de Lyon
Centre hospitalier universitaire Henri-Mondor
Centre Hospitalier Universitaire de Limoges
Universitätsspital Basel
Drug name mappings:
name: 利妥昔单抗
lang: CN
name: Rituximab
lang: EN
name: リツキシマブ（遺伝子組換え）
lang: JP